Literature DB >> 25047522

[Rational imaging of hepatocellular carcinoma. The challenge of multimodal diagnostic criteria].

A Kircher1, G Bongartz, E M Merkle, C J Zech.   

Abstract

CLINICAL/METHODICAL ISSUE: Both computed tomography (CT) and magnetic resonance imaging (MRI) constitute the gold standard in radiological imaging of hepatocellular carcinoma (HCC). In cases of typical contrast behavior each modality as a single dynamic technique allows the diagnosis of HCC. There is still a challenge in detection of small HCCs < 2 cm, in differentiating HCC and high-grade dysplasia from other benign liver lesions as well as the evaluation of hypovascular liver lesions in the cirrhotic liver. PERFORMANCE: Nowadays, both modalities achieve high detection rates of 90-100 % for lesions > 2 cm. Regarding lesions between 1 and 2 cm there is a higher sensitivity for MRI ranging between 80 and 90 % compared to 60-75 % with CT. Besides the multimodal diagnostic criteria, MRI provides significant benefits with the use of hepatobiliary contrast. Especially in combination with diffusion- weighted imaging (DWI) increased sensitivity and diagnostic accuracy compared to CT has been described for lesions sized < 2 cm. Regarding the differentiation from other hepatic nodules in the cirrhotic liver there is strong evidence that the coexistence of arterial enhancement and hypointensity on hepatobiliary imaging is specific for HCC. Moreover, hypointensity on hepatobiliary imaging is associated with a high positive predictive value (PPV) of up to 100 % for the presence of high-grade dysplasia and HCC. ACHIEVEMENTS: The use of MRI including hepatobiliary imaging and DWI has to be regarded as the best non-invasive imaging modality for the detection of HCC and for the characterization of nodules in patients with liver cirrhosis. In comparison to CT there are benefits regarding detection of small lesions < 2 cm and evaluation of hypovascular liver lesions in the context of the hepatocarcinogenesis including prognostic values of premalignant lesions. PRACTICAL RECOMMENDATIONS: Both MRI and CT provide a high diagnostic performance in evaluation of HCC in liver cirrhosis. With MRI there are considerable advantages regarding the detection rate and specificity. For daily clinical routine, CT offers a fast, reliable and easy available modality with benefits for patients in reduced general state of health and restricted compliance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25047522     DOI: 10.1007/s00117-014-2652-4

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  49 in total

Review 1.  [Modern visualization of the liver with MRT. Current trends and future perspectives].

Authors:  C J Zech; S O Schoenberg; K A Herrmann; O Dietrich; M I Menzel; T Lanz; A Wallnöfer; T Helmberger; M F Reiser
Journal:  Radiologe       Date:  2004-12       Impact factor: 0.635

2.  Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.

Authors:  Utaroh Motosugi; Tomoaki Ichikawa; Hironobu Sou; Katsuhiro Sano; Licht Tominaga; Ali Muhi; Tsutomu Araki
Journal:  Radiology       Date:  2010-07       Impact factor: 11.105

3.  Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.

Authors:  Peng-Ju Xu; Fu-Hua Yan; Jian-Hua Wang; Yan Shan; Yuan Ji; Cai-Zhong Chen
Journal:  J Comput Assist Tomogr       Date:  2010-07       Impact factor: 1.826

4.  Evaluation of hypervascular hepatocellular carcinoma in cirrhotic liver: comparison of different concentrations of contrast material with multi-detector row helical CT--a prospective randomized study.

Authors:  Keitaro Sofue; Masakatsu Tsurusaki; Ryota Kawasaki; Masahiko Fujii; Kazuro Sugimura
Journal:  Eur J Radiol       Date:  2010-11-09       Impact factor: 3.528

Review 5.  Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.

Authors:  Masatoshi Kudo
Journal:  Oncology       Date:  2008-12-17       Impact factor: 2.935

6.  Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection of hepatocellular carcinoma.

Authors:  J Stoker; M G Romijn; R A de Man; J T Brouwer; G J Weverling; J M van Muiswinkel; P E Zondervan; J S Laméris; J N M Ijzermans
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

7.  Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT.

Authors:  Bo Kiung Kang; Jae Hoon Lim; Seung Hoon Kim; Dongil Choi; Hyo Keun Lim; Won Jae Lee; Soon Jin Lee
Journal:  Radiology       Date:  2003-01       Impact factor: 11.105

Review 8.  MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA.

Authors:  Christoph J Zech; Karin A Herrmann; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Magn Reson Med Sci       Date:  2007       Impact factor: 2.471

Review 9.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Authors:  Peter Reimer; Günter Schneider; Wolfgang Schima
Journal:  Eur Radiol       Date:  2004-02-25       Impact factor: 5.315

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.